Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Oncolytic HSV-1 rRp450|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Oncolytic HSV-1 rRp450||rRp450||Oncolytic HSV-1 rRp450 is an engineered oncolytic type-I herpes simplex virus 1 (HSV-1) that encodes CYP2B1, which activates cancer prodrugs including cyclophosphamide and enhances sensitivity to chemotherapy agents, potentially resulting in increased tumor cell lysis and reduced metastases (PMID: 12209705).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colon carcinoma||not applicable||Cyclophosphamide + Oncolytic HSV-1 rRp450||Preclinical - Cell culture||Actionable||In a preclinical study, addition of Cytoxan (cyclophosphamide) to Oncolytic HSV-1 rRp450 treatment enhanced cytotoxicity in a colon carcinoma cell line in culture, and reduced colon carcinoma liver metastases in a mouse model (PMID: 12209705).||12209705|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|